

06th November, Chandigarh, India



"DIA LEAGUE":

"The Dia League CME was held at Chandigarh under the banner of Asian Society of Continuing Medical Education.

The CME was designed to get all the Diabetologist, Endocrinologist and General Physician on one platform for exchanging their views and sharing their clinical experiences with others about the challenges in the management of Diabetes. Well known Diabetologist, Endocrinologist and General Physician were invited to share their knowledge and Experience.

The Introductory speech was given by Asian Society. He emphasized the main role played by Asian Society of Continuing Medical Education and how important it is to spread the knowledge known to select few to the practicing Doctors at large.

The CME was attended by 53 Doctors all round India.

Date:

• 06th November 2016

Places and Venues:

• Hotel Grant Hyatt, Chandigarh.

Faculty:

Moderator:

• Dr. B. S. Bhatia

Chairpersons:

- Dr. Rakesh Arora
- Dr. Anurag Sharma
- Dr. V. K. Arya
- Dr. G. P. Malik

Speaker Topic wise:

- Dr. S. K. Mathur
- Dr. Amardeep Garg
- Dr. D. Chakravartty
- Dr. Jubbin Jacob
- Dr. Manikant Singla
- Dr. Rajat Gupta
- Dr. A. P. Singh

TOPICS-

- DPP-4 Inhibitors: Have we optimized their role in the treatment of patients with Type 2 Diabetes.
- Placement of Sulphonylurea in the present scenario?
- The role of combination therapies in early, Intensive management of newly diagnosed Type 2 Diabetes with marked glycaemia.
- The act of balancing between the newer treatment options in T2DM
 - 1. Yes to DPPIV Inhibitors.
 - 2. Yes to SGLT2 Inhibitors
- Cross Talk: Managing Diabetic patient with CV comorbid conditions
 - 1. Cardiologist perspective
 - 2. Diabetologist perspective
- Futuristic Vision in Diabetes Mellitus.

- Dr. Rajat Gupta talked on DPP-4 Inhibitors: Have we optimized their role
 in the treatment of patients with Type 2 Diabetes and covered below
 mention topics in detail
 - ✓ What are incretins?
 - ✓ Gastric Inhibitory Polypeptide (GIP)
 - ✓ GLP-1 Effects in Humans
 - ✓ Dipeptidyl Peptidase-IV Antagonists , Its Safety and Efficacy
 - ✓ Glimipiride vs Vildagliptin Asian study
 - ✓ Cardiovascular Safety
 - ✓ Most common side effects
 - ✓ Weight and DPP4 inhibitors
 - ✓ Gliptin: no weight gain
 - ✓ Cardiovascular Effects
 - ✓ Glycemic Varibility
 - ✓ DPP IV Inhibitors and CV Events
 - ✓ Merits over SGLT2 Inhibitors
- **Dr. A. P. Singh** talked on Placement of Sulphonylurea in the present scenario?

The summary of topic is -

- ✓ Insulin Secretion (Glimepiride)
- ✓ Therapeutic actions
- ✓ Attributes of sulfonylureas
- ✓ Type 2 Diabetes is a Dual Problem
- ✓ Unique Dual Mode of Action
- ✓ Acting on Both Phases of Insulin Secretion
- ✓ Glimepiride Controls Glycemia with Less Insulin Secretion
- ✓ Glimepiride : Efficacy Proven in Monotherapy
- ✓ Efficacy: Glimepiride + Gliptin Combination
- ✓ Safety: Hypoglycemia vs Glibenclamide
- ✓ University Group Diabetes Program
- ✓ Cardiovascular Safety: Ischemic Preconditioning
- ✓ Research Design and methods
- ✓ Advantages of Metformin + Sulphonylurea Combination
- ✓ SU role in management
- ✓ Special situation

- **Dr. D. Chakravartty** talked on Futuristic Vision in Diabetes Mellitus, topics covered was—
 - ✓ Insulin Jet Injectors
 - ✓ Continuous Glucose Monitoring System (CGMS)
 - ✓ REAL-Time Continuous Glucose Monitoring System
 - ✓ CGM in T1DM: JDRF Sensor Trial.
- Dr. A. P. Sodhi talked on The role of combination therapies in early,
 Intensive management of newly diagnosed Type 2 Diabetes with marked glycaemia, topics covered was
 - ✓ Provide practical guidance on improving diabetes care through highlighting the need for a sense of urgency in treating to target
 - ✓ Earlier introduction of combination therapy
 - ✓ Consideration of patient profile
 - ✓ Use of combinations of drugs with complementary mechanisms of action Diabetes Mellitus A Constellation of Complications
 - ✓ Need for an early and intensive approach to type 2 diabetes management Pharmacotherapy in T2DM Checklist.
- **Dr. S. K. Mathur** talked on Yes to DPP4 Inhibitor, The scientific session highlighted following topics
 - ✓ Comparing Dpp Iv Inhibitors
 - ✓ Comparing Sglt-2 Inhibitors
 - ✓ Gliptin Mechanism of action
 - ✓ Physiological Actions of GLP-1 and GIP
 - ✓ Comparison of DPP–4 Inhibitors
 - ✓ DPP4 Inhibitors Efficacy

- **Dr. Manikant Singla** talked on Yes to SGLT2 Inhibitor, The scientific session highlighted following topics
 - ✓ Unmet Needs With Conventional Antihyperglycemic Therapies
 - ✓ The Kidneys Play an Important Role in Glucose Control
 - ✓ Mechanism Of Action
 - ✓ Altered Renal Glucose Control in Diabetes
 - ✓ Highlighted Rationale for SGLT2 Inhibitors
 - ✓ What are the Effects of SGLT2 Inhibitors
- Dr. Amardeep Garg talked on Managing Diabetic patient with CV comorbid conditions – Cardiologist Perspective, The scientific session highlighted following topics –
 - ✓ Mechanisms by which Diabetes Mellitus leads to CHD.
 - ✓ Cardiac morbidities due to diabetics.
 - ✓ Metabolic Syndrome: Risk of Developing DM.
 - ✓ Diabetes Mellitus: Risk of Myocardial Infarction.
 - ✓ BP Goals in People with Diabetes.
- Dr. Jubbin Jacob talked on Managing Diabetic patient with CV comorbid conditions – Diabetologist Perspective, The scientific session highlighted following topics –
 - ✓ Components Of Comprehensive Diabetes Evaluation
 - ✓ Glycemic Recommendations for Non-Pregnant Adults with Diabetes.
 - ✓ Is HbA1c Affected by Glycemic Instability?
 - ✓ Chronic hyperglycemia vs. Frequent acute glycemic variability Drugs used in the management

Feedback:

Suggested topics from delegates interested for future cme -

- Insulin Management in ICU
- DP 4 Inhibitors
- Gestational Diabetes
- Type 1 DM Insulin dosage
- Diabetes and its Complications `
- Role of OHA in GDM
- Hypertension & Diabetes
- Infection disease
- Thyroid Disorders & Complications approach.
- HTN, IHD.
- Recent Hands in Bariatic Surgery in DM.
- HTN
- Diabetic Nephropathy
- Cerebrovascular Accident
- Osteoarthritis
- Diabetes Latest Trends in Clinical Practice
- IHD

PHOTO'S





















